Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)

The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV. The main question to answer is if the presence of HPV DNA in the blood one month after the treatment is useful in detecting remaining tumour or relapse within two years after treatment. The participants will be asked to provide blood tests: 1. before treatment 2. weekly during the treatment 3. on all scheduled follow-up appointments 4. on all unplanned appointments where a relapse is suspected

NCT Number	NCT05649865
Lead Sponsor	Region Skane
Conditions	Oropharynx Squamous Cell Carcinoma
Enrollment	150 participants
Start Date	2023-05-15
Primary Completion	2027-05 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2023-06-08